Carbonic anhydrase VI: a novel marker for salivary serous acinar differentiation and its application to discriminate acinic cell carcinoma from mammary analogue secretory carcinoma of the salivary gland

2015 ◽  
Vol 68 (5) ◽  
pp. 641-647 ◽  
Author(s):  
Min-Shu Hsieh ◽  
Yung-Ming Jeng ◽  
Yu-Lin Jhuang ◽  
Yueh-Hung Chou ◽  
Chiao-Ying Lin
Keyword(s):  
Salivary Gland ◽  
Carbonic Anhydrase ◽  
Cell Carcinoma ◽  
Acinic Cell Carcinoma ◽  
Secretory Carcinoma ◽  
Mammary Analogue Secretory Carcinoma ◽  
Acinic Cell ◽  
Carbonic Anhydrase Vi

scholarly journals Mammary Analogue Secretory Carcinoma

2016 ◽  
Vol 140 (9) ◽  
pp. 997-1001 ◽  
Author(s):  
Todd M. Stevens ◽  
Vishwas Parekh
Keyword(s):  
Salivary Gland ◽  
Cell Carcinoma ◽  
Salivary Gland Tumor ◽  
Acinic Cell Carcinoma ◽  
Low Grade ◽  
Secretory Carcinoma ◽  
Duct Carcinoma ◽  
Mammary Analogue Secretory Carcinoma ◽  
Acinic Cell ◽  
Not Otherwise Specified

Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland tumor that shares the same histologic appearance and ETV6 gene (12p13) rearrangement as secretory carcinoma of the breast. Prior to its recognition, MASC cases were commonly labeled acinic cell carcinoma and adenocarcinoma, not otherwise specified. Despite distinctive histologic features, MASC may be difficult to distinguish from other salivary gland tumors, in particular zymogen-poor acinic cell carcinoma and low-grade salivary duct carcinoma. Although characteristic morphologic and immunohistochemical features form the basis of a diagnosis of MASC, the presence of an ETV6-NTRK3 gene fusion is confirmatory. Given its recent recognition the true prognostic import of MASC is not yet clearly defined.

Usefulness of immunohistochemistry to distinguish between secretory carcinoma and acinic cell carcinoma in the salivary gland

2020 ◽  
Author(s):  
Yuichiro Hamamoto ◽  
Hiroshi Harada ◽  
Masaharu Kohara ◽  
Keiichiro Honma ◽  
Shin-ichi Nakatsuka ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Cell Carcinoma ◽  
Acinic Cell Carcinoma ◽  
Secretory Carcinoma ◽  
Acinic Cell

scholarly journals Utility of Immunohistochemistry and ETV6 (12p13) Gene Rearrangement in Identifying Secretory Carcinoma of Salivary Gland among Previously Diagnosed Cases of Acinic Cell Carcinoma

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Rana Naous ◽  
Shengle Zhang ◽  
Alfredo Valente ◽  
Melissa Stemmer ◽  
Kamal K. Khurana
Keyword(s):  
Salivary Gland ◽  
Cell Carcinoma ◽  
Gene Rearrangement ◽  
Genetic Alterations ◽  
Interstitial Deletion ◽  
Acinic Cell Carcinoma ◽  
Secretory Carcinoma ◽  
Acinic Cell ◽  
S 100 ◽  
Initial Description

Objective. Secretory carcinoma is a recently described entity with characteristic immunoprofile and ETV6 (12p13) rearrangement. Before its initial description, it was generally diagnosed as acinic cell carcinoma (ACCi). We evaluated immunoprofile and ETV6 rearrangement in cytological and surgical cases of previously diagnosed ACCi, in an attempt to identify any misclassified SC. Methods. Fifteen cytology and surgical cases of ACCi diagnosed over a 13-year period were retrieved and subjected to immunohistochemistry for S-100, mammaglobin, GATA-3 and DOG-1 as well as FISH for ETV6 (12p13). Results. Of the 8 cytology cases, only 1 was positive for S100, GATA-3, and mammaglobin, and negative for DOG-1. It also demonstrated ETV6 rearrangement and was reclassified as SC. The same immunoprofile was present in 2 of the 13 surgical cases. ETV6 rearrangement characterized by 3′ interstitial deletion was detected in one of these cases and was reclassified as SC. Immunohistochemistry and ETV6 rearrangement were useful in identifying 2 (13.3%) cases misclassified as ACCi. Conclusions. Characteristic immunoprofile and ETV6 gene rearrangement may prove useful in identifying cases of SC. The presence of ETV6 3′ interstitial deletion in one of our cases suggests that there may be additional ETV6 related genetic alterations contributing to the pathogenesis of SC.

Sign in / Sign up

Export Citation Format

Share Document